Cytokine Levels in Conversion Disorder

NCT ID: NCT00971360

Last Updated: 2010-10-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-09-30

Study Completion Date

2010-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is whether the proinflammatory cytokine levels in patients with conversion disorder is increased or not changed in the acute phase and subacute - chronic periode, compared with controls.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Conversion Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Conversion disorder

conversion disorder

Intervention Type OTHER

Proinflammatory cytokine levels in conversion disorder

Healthy control

conversion disorder

Intervention Type OTHER

Proinflammatory cytokine levels in conversion disorder

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

conversion disorder

Proinflammatory cytokine levels in conversion disorder

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinical diagnosis of Alzheimer's Disease

Exclusion Criteria

* Autoimmune disease
* Neurological disease
* Any organic disorder that could possibly affect proinflammatory cytokines
* Pregnancy
* Any drug usage within 2 weeks
* Any active or passive immunization within 6 months
* Any other DSM-IV axis I psychiatric disorder
* Mental retardation
* Developmental disorder of childhood
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Trakya University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Trakya University Scientific Research Unit (TUBAB)

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Trakya University Faculty of Medicine; Department of Psychiatry

Edirne, , Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

References

Explore related publications, articles, or registry entries linked to this study.

Rief W, Pilger F, Ihle D, Bosmans E, Egyed B, Maes M. Immunological differences between patients with major depression and somatization syndrome. Psychiatry Res. 2001 Dec 31;105(3):165-74. doi: 10.1016/s0165-1781(01)00338-9.

Reference Type BACKGROUND
PMID: 11814536 (View on PubMed)

Ziemssen T, Kern S. Psychoneuroimmunology--cross-talk between the immune and nervous systems. J Neurol. 2007 May;254 Suppl 2:II8-11. doi: 10.1007/s00415-007-2003-8.

Reference Type BACKGROUND
PMID: 17503136 (View on PubMed)

Dantzer R. Somatization: a psychoneuroimmune perspective. Psychoneuroendocrinology. 2005 Nov;30(10):947-52. doi: 10.1016/j.psyneuen.2005.03.011.

Reference Type BACKGROUND
PMID: 15949897 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

TUTFEK 2009/173

Identifier Type: -

Identifier Source: org_study_id